Literature DB >> 22651975

Learning from the past: historical aspects of bacterial toxins as pharmaceuticals.

Sabine Pellett1.   

Abstract

Botulinum neurotoxins are the most poisonous substances known to humankind, but also are the bacterial toxins most frequently used as pharmaceuticals to benefit humans. The discovery of botulinum toxins and development into a useful drug is unique and fascinating, dating back to the early 19th century, when Justinus Kerner first recognized that botulism was caused by a biological toxin and suggested its use for medicinal purposes. This was translated into reality in 1980, when Alan Scott for the first time used the toxins to successfully treat strabismus. Now a subset of botulinum toxins are widely used for cosmetic applications, treatment of various movement disorders, pain and many other syndromes, and further developments using other botulinum toxins or recombinant molecules engineered from subdomains are promising.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22651975     DOI: 10.1016/j.mib.2012.05.005

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  6 in total

Review 1.  Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery.

Authors:  Erkan Kiris; Krishna P Kota; James C Burnett; Veronica Soloveva; Christopher D Kane; Sina Bavari
Journal:  Expert Rev Mol Diagn       Date:  2014-01-23       Impact factor: 5.225

2.  Transynaptic Action of Botulinum Neurotoxin Type A at Central Cholinergic Boutons.

Authors:  Matteo Caleo; Matteo Spinelli; Francesca Colosimo; Ivica Matak; Ornella Rossetto; Zdravko Lackovic; Laura Restani
Journal:  J Neurosci       Date:  2018-10-12       Impact factor: 6.167

Review 3.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 4.  Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.

Authors:  Nebojsa Nick Knezevic; Ajay Yekkirala; Tony L Yaksh
Journal:  Anesth Analg       Date:  2017-11       Impact factor: 5.108

Review 5.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

Review 6.  AbobotulinumtoxinA: A 25-Year History.

Authors:  Gary D Monheit; Andy Pickett
Journal:  Aesthet Surg J       Date:  2017-05-01       Impact factor: 4.283

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.